{
    "clinical_study": {
        "@rank": "48687", 
        "acronym": "aboundsqm", 
        "arm_group": [
            {
                "arm_group_label": "Abraxane + Best Supportive Care (BSC)", 
                "arm_group_type": "Experimental", 
                "description": "Dosing will occur in two phases - induction and maintenance.  During induction, the subject will receive Abraxane plus carboplatin as standard of care.  At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase.  Maintenance dosing on this arm includes Abraxane plus best supportive care."
            }, 
            {
                "arm_group_label": "Best Supportive Care (BSC)", 
                "arm_group_type": "Other", 
                "description": "Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only."
            }
        ], 
        "brief_summary": {
            "textblock": "Maintenance treatment of advanced stage squamous cell NSCLC"
        }, 
        "brief_title": "Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Carcinoma, Squamous Cell", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase III, randomized, open-label, cross-over, multicenter study of nab-paclitaxel plus\n      best palliative care or best palliative care alone as maintenance treatment after response\n      or stable disease with nab-paclitaxel plus carboplatin as induction in subjects with\n      squamous cell NSCLC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Age \u2265 18 years of age at the time of signing the Informed Consent Form. 2.\n             Understand and voluntarily provide written consent to the Informed Consent Form prior\n             to conducting any study related assessments/procedures.\n\n             3. Able to adhere to the study visit schedule and other protocol requirements Disease\n             Specific 4. Histologically or cytologically confirmed Stage IIIB or IV squamous cell\n             Non Small Cell Lung Cancer at study entry.\n\n             5. No prior history of other malignancies, except basal cell carcinoma of the skin,\n             squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n\n             6. Radiographically documented measurable disease at study entry (as defined in\n             Appendix A; lesions in previously irradiated areas [or areas with local therapy]\n             should not be selected as target lesions, unless there has been demonstrated\n             progression in the lesion).\n\n             7. No prior chemotherapy for the treatment of metastatic disease at study entry.\n             Adjuvant chemotherapy is permitted providing cytotoxic chemotherapy was completed 12\n             months prior to starting the study and without disease recurrence.\n\n             8. Absolute neutrophil count \u2265 1500 cells/mm3. 9. Platelets \u2265 100,000 cells/mm3. 10.\n             Hemoglobin \u2265 9 g/dL. 11. Aspartate transaminase/serum glutamic oxaloacetic\n             transaminase, alanine transaminase/serum glutamic pyruvic transaminase \u2264 2.5 \u00d7 upper\n             limit of normal range or \u2264 5.0 \u00d7 upper limit of normal range if liver metastases.\n\n             12. Total bilirubin \u2264 1.5 \u00d7 upper limit of normal range except in cases of Gilbert's\n             disease and liver metastases.\n\n             13. Creatinine \u2264 1.5 mg/dL. 14. Expected survival of > 12 weeks for the Induction\n             part of the study. 15. Eastern Cooperative Oncology Group performance status 0 or 1.\n             16. For Maintenance part of the study, subjects must have received at least one dose\n             of nab-paclitaxel in each of the 4 cycles during Induction Pregnancy 17. Females of\n             childbearing potential [defined as a sexually mature woman who (1) have not undergone\n             hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the\n             surgical removal of both ovaries) or (2) have not been naturally postmenopausal for\n             at least 24 consecutive months (ie, has had menses at any time during the preceding\n             24 consecutive months)] must:\n\n               1. Have a negative pregnancy test as verified by the study doctor prior to starting\n                  study therapy. She must agree to ongoing pregnancy testing during the course of\n                  the study, and after end of study therapy. This applies even if the subject\n                  practices true abstinence* from heterosexual contact.\n\n               2. Either commit to true abstinence* from heterosexual contact (which must be\n                  reviewed on a monthly basis) or agree to use, and be able to comply with,\n                  effective contraception without interruption, 28 days prior to starting study\n                  drug, during the study therapy (including dose interruptions), and for 3 months\n                  after discontinuation of study therapy.\n\n                  Male subjects must:\n\n               3. practice true abstinence* or agree to use a condom during sexual contact with a\n                  pregnant female or a female of childbearing potential while participating in the\n                  study, during dose interruptions and for at least 3 months following study drug\n                  discontinuation, even if he has undergone a successful vasectomy.\n\n                  * True abstinence is acceptable when this is in line with the preferred and\n                  usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation,\n                  symptothermal, post-ovulation methods) and withdrawal are not acceptable methods\n                  of contraception].\n\n                  18. Females must abstain from breastfeeding during study participation and 3\n                  months after IP discontinuation.\n\n                  Exclusion Criteria:\n\n          -  The presence of any of the following will exclude a subject from enrollment into the\n             Induction, Maintenance, or Cross-over parts of the study (except if specified at\n             study entry only):\n\n               1. Evidence of active brain metastases, including leptomeningeal involvement (prior\n                  evidence of brain metastasis are permitted only if treated and stable and off\n                  therapy for \u2265 42 days prior to signing Informed Consent Form).\n\n               2. Only evidence of disease is non measurable at study entry.\n\n               3. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology\n                  Criteria for Adverse Events v4.0).\n\n               4. Venous thromboembolism within 6 months prior to signing Informed Consent Form.\n\n               5. Current congestive heart failure (New York Heart Association class II-IV).\n\n               6. Myocardial infarction within 6 months prior to signing Informed Consent Form.\n\n               7. Treatment with any investigational product within 28 days prior to signing\n                  Informed Consent Form.\n\n               8. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin.\n\n               9. Currently enrolled in any other clinical protocol or investigational trial that\n                  involved administration of experimental therapy and/or therapeutic devices.\n\n              10. Any other clinically significant medical condition and/or organ dysfunction that\n                  will interfere with the administration of the therapy according to this\n                  protocol.\n\n              11. Any condition including the presence of laboratory abnormalities, which places\n                  the subject at unacceptable risk if he/she were to participate in the study.\n\n              12. Any condition that confounds the ability to interpret data from the study.\n\n              13. Pregnant and nursing females."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027428", 
            "org_study_id": "ABI-007-NSCL-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abraxane + Best Supportive Care (BSC)", 
                "description": "100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care", 
                "intervention_name": "Abraxane  (Induction)", 
                "intervention_type": "Drug", 
                "other_name": "nab-paclitaxel"
            }, 
            {
                "arm_group_label": "Abraxane + Best Supportive Care (BSC)", 
                "description": "6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion", 
                "intervention_name": "Carboplatin (Induction)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Abraxane + Best Supportive Care (BSC)", 
                "description": "100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care", 
                "intervention_name": "Abraxane (Maintenance)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Abraxane + Best Supportive Care (BSC)", 
                "description": "The best palliative care per investigator (including but not limited to:  antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents", 
                "intervention_name": "Best Supportive Care (Maintenance)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Best Supportive Care (BSC)", 
                "description": "100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care", 
                "intervention_name": "Abraxane  (Induction)", 
                "intervention_type": "Drug", 
                "other_name": "nab-paclitaxel"
            }, 
            {
                "arm_group_label": "Best Supportive Care (BSC)", 
                "description": "6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care", 
                "intervention_name": "Carboplatin (Induction)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Best Supportive Care (BSC)", 
                "description": "The best palliative care per investigator (including but not limited to:  antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents", 
                "intervention_name": "Best Supportive Care (Maintenance)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Nab-paclitaxel", 
            "Albumin bound paclitaxel", 
            "Taxanes", 
            "Maintenance trials", 
            "Celgene", 
            "Abraxane", 
            "ABI-007", 
            "NSCLC", 
            "Non-Small Cell Lung Cancer", 
            "Cancer of the Lung", 
            "Carcinoma, Squamous Cell", 
            "Lung Neoplasms", 
            "Abound.sqm"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "Regional Cancer Care Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77090"
                    }, 
                    "name": "Millennium Oncology"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane\u00ae) as Maintenance Treatment After Induction With Nab-Paclitaxel (Abraxane\u00ae) Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)", 
        "overall_contact": {
            "email": "dnguyen@celgene.com", 
            "last_name": "Duong Ngyuen, Pharm. D.", 
            "phone": "(415) 839-7097"
        }, 
        "overall_contact_backup": {
            "email": "jsheikh@celgene.com", 
            "last_name": "Jenny Sheikh, BA", 
            "phone": "732-652-6318"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Teng Jin Ong, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of participants to survive without progressing", 
            "measure": "Progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 5 years"
            }, 
            {
                "description": "Number of participants who survive", 
                "measure": "Overall Survival", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 5 years"
            }, 
            {
                "description": "The percentage of patients who achieve an overall response according to Response Evaluation Criteria in Solid Tumors RECIST 1.1 guidelines", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Approximately 5 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}